Mangalam Drugs and Organics Limited announced the outcome of its Board Meeting held on January 15, 2026. The Board approved the Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended January 15, 2026, along with the Limited Review Report. The meeting, which commenced at 12:00 PM and concluded at 2:30 PM, also accepted the resignation of Mr. Ajay Samant, Chief Financial Officer, effective January 31, 2026, due to health reasons. Additionally, the Board took note of the resignation of Ms. Anuradha Pandey, Company Secretary & Compliance Officer, effective March 29, 2026, to pursue other career opportunities.

The company reported a Net Loss of ₹983.55 Lakhs for the quarter ended December 31, 2025, on a consolidated basis, compared to a Net Profit of ₹128.68 Lakhs in the same period last year. For the nine months ended December 31, 2025, the consolidated Net Loss stood at ₹3,098.01 Lakhs, against a Net Profit of ₹666.13 Lakhs in the prior year period. Standalone results mirrored a similar trend, with a Net Loss of ₹977.94 Lakhs for the quarter and ₹3,075.38 Lakhs for the nine months ended December 31, 2025.

The Board also noted that the statutory auditors have not expressed any modified opinions in their audit reports for the Un-Audited Financial Results. The final hearing for the scheme of Merger by Absorption of Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited with Mangalam Drugs and Organics Limited is scheduled for March 10, 2026.